Advanced search
Start date

Effects of cannabidiol (CBD) in an animal model of Alzheimer's disease induced by streptozotocin

Grant number: 22/09866-0
Support Opportunities:Scholarships abroad - Research Internship - Master's degree
Effective date (Start): January 30, 2023
Effective date (End): July 29, 2023
Field of knowledge:Biological Sciences - Pharmacology - Neuropsychopharmacology
Principal Investigator:Alessandra Mussi Ribeiro
Grantee:Gabrielle Christine Pereira
Supervisor: Erika Gyengesi
Host Institution: Instituto de Saúde e Sociedade (ISS). Universidade Federal de São Paulo (UNIFESP). Campus Baixada Santista. Santos , SP, Brazil
Research place: Western Sydney University, Sydney, Australia  
Associated to the scholarship:21/12409-7 - Investigation of the effects of cannabidiol (CBD) in an animal model of Alzheimer's Disease induced by streptozotocin, BP.MS


Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the most common cause of types of dementia in the elderly. Studies have pointed out as a possible mediator of neurodegeneration the early deficiency in brain glucose metabolism and insulin signaling pathway, resulting in oxidative stress processes, increase in the production of A² peptide and hyperphosphorylated tau protein, mitochondrial dysfunction, activation of molecules pro-inflammatory, activation of astrocytes and microglia, and apoptosis. Currently, one of the main challenges is the development of novel drugs that prevent the progression and/or the emergence of AD. In this context, bioactive compounds derived or isolated from plants may have antioxidant and anti-inflammatory activities with potential neuroprotective effects in neurodegenerative diseases. The aim of this study is to evaluate the potential neuroprotective effect of cannabidiol (CBD) in a pharmacological model of AD, induced by streptozotocin (STZ) in Wistar rats. Firstly, animals will receive an injection of STZ (3 mg/kg, via i.c.v.), after each rat will be treated with CBD (10 mg/kg, i.p.) or vehicle for 14 days. Sucrose preference tests, open field, olfactory sensitivity, spontaneous alternation, and new object recognition tasks will be performed throughout the treatment. At the end of the treatment, the brains will be collected to perform immunohistochemistry for A² and Tau and inflammatory cytokines (IL1 ² and IL-6) and dosages of oxidative stress parameters (lipid peroxidation and activity of the enzymes catalase, superoxide dismutase, and glutathione peroxidase) in the brain areas of the olfactory bulb, hippocampus, and cerebral cortex. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.